Background: Full-field digital mammography (FFDM) has replaced screen-film mammography (SFM) in most breast screening programs. We analyzed the impact of this replacement on the screening outcome.
introduction
Many Western countries have implemented regional or nationwide screening mammography programs with the aim of detecting breast malignancies at an early stage [1] . Highquality, full-field digital mammography (FFDM) has been available now for several years and has replaced screen-film mammography (SFM) in most programs. FFDM improves workflow and is at least as effective as SFM in the detection of breast cancer [2, 3] . However, higher cancer detection rates at FFDM may be accompanied by increased referral rates [4, 5] and lower positive predictive values of referral for breast cancer [6, 7] . Moreover, FFDM especially increases the detection of ductal carcinoma in situ (DCIS), resulting in a larger proportion of breast cancers being over-diagnosed [8] .
The Netherlands has a long tradition in screening mammography, and transition to digital screening has also resulted in higher referral rates and a significantly enhanced cancer detection rate [6, 7] . Although emerging data become available with respect to digital screening accuracy, little is known about the effects of conversion of analog to digital screening on additional diagnostic tests, tumor stage, histology and biology of screen-detected cancers and surgical treatment of these cancers. In a southern breast cancer screening region of The Netherlands, we therefore carried out a comprehensive evaluation of the changes in the referral rate, cancer detection rate, utilization of diagnostic tests after referral, characteristics of screen-detected cancers and surgical treatment procedures following the introduction of digital screening mammography.
materials and methods

study population
We included a consecutive series of 60 770 analog screens in 60 770 women (6851 initial screens and 53 919 subsequent screens) and 63 182 digital screens in 63 182 women (7019 initial screens and 56 163 subsequent screens), obtained at three specialized screening units in a southern biennial screening mammography region of The Netherlands (BOZ, Bevolkings Onderzoek Zuid) between 1 January 2008 and 1 January 2011. Of the 56 163 women with a subsequent digital screen, 29 649 were also represented in the cohort of 60 770 women who had received an analog screen between 1 January 2008 and 1 January 2011. SFM was replaced by FFDM on, respectively, 26 May 2009, 3 June 2009 and 6 April 2010 at the three units. To determine the possible presence of a learning curve since the start of digital screening, we divided the total number of digital screens in each screening unit in two equal proportions for which we then separately assessed the screening outcome. All women had given written informed consent to use their screening and follow-up data for evaluation purposes. Ethical approval for this study was waived by the Central Committee on Research Involving Human Subjects (CCMO) in The Hague, The Netherlands.
screening procedure and referral Details of our breast cancer screening program, offering biennial screening mammography for women aged 50-75 years, have been described previously [9, 10] . In brief, screen-film mammograms were obtained with commercially available units (Performa, Oldelft, Tuusula, Finland). Dedicated mammography screens were utilized (Mamoray MR-R, Agfa, Schroenhausen, Germany). Both dedicated film (Mamoray HDR; Agfa, Mortsel, Belgium) and extended-cycle dedicated processing were used. All digital mammograms were acquired with a Lorad Selenia FFDM system (Hologic, Inc., Danbury, CT), with a 70 μm pixel size and a 232 × 286 mm 2 field of view. All mammograms were obtained by specialized screening mammography technologists and double-read by a team consisting of 11 certified screening radiologists. Prior screening mammograms were always available for comparison at the time of subsequent screening. To facilitate soft copy reading of subsequent screening examinations at FFDM, the most recent prior screen-film screening mammograms were digitized using a film scanner and archiver designed for mammography (DigitalNow; R2/ Hologic). The original hard copy screen film mammograms were also available for viewing if desired by the screening radiologist. Women with normal or benign mammographic findings, or with a non-specific minimal sign [11] , were not referred. If screening mammography showed a suspicious or malignant lesion, the woman was referred to a surgical oncologist or breast clinic for further analysis of the mammographic abnormality. For each referral, the screening radiologists classified the abnormal mammographic findings according to one of five categories: suspicious high density (e.g. speculated density or density with indistinct borders), suspicious microcalcifications (e.g. pleomorphic, branching or amorphous/indistinct microcalcifications), high density in combination with microcalcifications, architectural distortion or asymmetry. Women with discrepant readings at screening mammography (only one of the two screening radiologists considered referral necessary) were always referred for further analysis. diagnostic workup and surgical treatment of screen-detected cancers A total of 15 regional and university hospitals were involved in the assessment of screen-positive women. After physical examination by the surgeon, additional mammographic views were obtained if necessary. At a diagnostic workup, radiologists classified the radiological findings according to the American College of Radiology BI-RADS [12] . BI-RADS 4 and BI-RADS 5 lesions were routinely biopsied, whereas BI-RADS 3 lesions were either biopsied or followed up with mammography. Dependent on the findings at physical examination and mammography and dependent on the diagnostic workup protocols and hospital facilities available, further diagnostic evaluation could include breast ultrasonography, magnetic resonance mammography, percutaneous fineneedle aspiration cytology or core biopsy or open surgical biopsy. During a 1 year follow-up, we collected data on diagnostic imaging procedures, biopsy specimen and surgical procedures of all the referred women. Breast cancers were divided into DCIS and invasive cancers; lobular carcinoma in situ was considered to be a benign lesion. Advanced cancers were defined as invasive cancers with tumor-node-metastases stage IIA or higher, i.e. tumor size exceeding 20 mm (T2) and/or the presence of lymphatic metastasis in the sentinel node or axillary lymph nodes [13] . Sentinel nodes were classified negative if they harbored isolated tumor cells or sub-micrometastases (<0.2 mm) and were considered positive (N+) if they contained micrometastases (0.2-2 mm) or macrometastases (>2 mm). For women with bilateral disease, the cancer with the highest stage was retained; multiple foci of cancer in one breast were counted as one cancer.
statistical analysis
All data were entered into a computerized spreadsheet (Excel; Microsoft, Redmond, WA). Statistics were carried out using the SAS program version 9.1.3 (Statistical Analysis Software; SAS/STAT software®, Cary, NC). A double-sided t-test was used to test differences between continuous variables, and the χ² test to test differences between categorical variables. The significance level was set at 5%.
results
overall screening results
Age distribution and the proportion of initial screens were comparable for SFM and FFDM ( Table 1 ). The referral rate and the overall cancer detection rate (the number of cancers per 1000 screened women) were significantly higher at FFDM [3.0% versus 1.5% (P < 0.001) and 6.6‰ versus 4.9‰ (P < 0.001), respectively]. The cancer detection rate at initial screens was similar to the one observed at subsequent screens (SFM: 4.7‰ versus 4.9‰, P = 0.8; FFDM: 7.65‰ versus 6.6‰, P = 0.3). The positive predictive value of referral was significantly lower at FFDM (21.9% versus 31.6%, P < 0.001). Per 1000 screened women, screen-detected DCIS increased from 0.7 at SFM to 1.6 at FFDM (P < 0.001) and invasive cancer from 4.2 at SFM to 5.1 at FFDM (P < 0.001). The proportion of DCIS among women with screen-detected cancers was significantly higher at FFDM (23.8% versus 14.8%, P = 0.003). Both the referral rate for suspicious microcalcifications per 1000 screens and the proportion of women referred for suspicious microcalcifications significantly increased at FFDM [from 2.5‰ at SFM to 9.2‰ at FFDM (P < 0.001) and from 16.2% at SFM to 30.2% at FFDM (P < 0.001), respectively; supplementary The referral rate, cancer detection rate and positive predictive value of referral at digital screening were similar for the first half and the second half of digitally obtained screens in each screening unit [2.9% versus 3.1% (P = 0.6), 6.9‰ versus 6.5‰ (P = 0.6) and 23.4% versus 20.8% (P = 0.7), respectively].
diagnostic workup
Almost half (49.0%) of the women referred at SFM or FFDM only received additional breast imaging at the diagnostic workup, and the number of women who only underwent breast imaging at workup almost doubled from 7.6 at SFM to 14.9 at FFDM per 1000 screens (P < 0.001; supplementary Table S2 , available at Annals of Oncology online). The other half of the referred women underwent biopsy in addition to breast imaging (either percutaneous biopsy, excisional biopsy or a combination of percutaneous and surgical biopsy). Among the different types of biopsy procedures, the use of stereotactic core needle biopsy most markedly increased after conversion from SFM to FFDM (from 2.2‰ analog screens to 7.9‰ digital screens, P < 0.001); the proportion of the referred women who underwent stereotactic core needle biopsy increased from 14.9% (140/940) at SFM to 26.4% (506/1919) at FFDM (P < 0.001). The increase in stereotactic core needle biopsy was mainly due to the increase in referral for microcalcifications. The positive predictive value of percutaneous biopsy decreased from 62.8% (297/473) at SFM to 42.9% (418/974) at FFDM (P < 0.001), and the highest drop in the positive predictive value was found for stereotactic core needle biopsy [from 40.0% (56/140) at SFM to 26.9% (136/ 506) at FFDM, P < 0.001].
tumor characteristics
Per 1000 screened women, there was a significant increase with FFDM versus SFM in the detection rate of low-and intermediate-grade DCIS (+0.7), invasive T1a-c cancers (+0.9), invasive ductal cancers (+0.9), low-grade (+1.1), node-negative invasive cancers (+1.2), estrogen-receptor-or progesteronereceptor-positive invasive cancers (respectively, +0.9 and +1.1) and Her2/Neu-negative invasive cancers (+0.8) ( Table 2) .
type of breast cancer surgery
Compared with women screened with SFM, a significantly higher proportion of women screened with FFDM underwent breast-conserving surgical treatment of their screen-detected cancer (82.9% versus 75.1%, P = 0.04, Table 1 ). The number of women undergoing breast-conserving surgery increased from 3.7‰ screened women at SFM to 5.5‰ women at FFDM (P = 0.04). A similar mastectomy rate of 1.1‰ screened women was observed at SFM and FFDM. discussion To our knowledge, the current population-based study is the first that provides a thorough overview of the impact of transition of SFM to FFDM on the screening outcome as well as on the diagnostic workup and surgical treatment. This transition resulted in a significantly increased referral rate and detection rate of DCIS and invasive cancers, in combination with a significantly decreased positive predictive value of referral and biopsy and an almost fourfold increase in the use of stereotactic core needle biopsy. Invasive cancers at FFDM were more likely to be diagnosed at an earlier tumor stage, showed a more favorable tumor grade and comprised a significantly larger proportion of progesterone-receptor-positive cancers. original articles
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Moreover, cancers detected at FFDM were more likely to be treated by breast-conserving surgery, whereas the mastectomy rate was comparable with the rate observed at SFM. Studies report conflicting results on the effect of implementation of digital mammography on the referral rate. Compared with SFM, a significantly higher referral rate [3-5, 7, 14, 15] was observed at FFDM in several European and US studies, whereas others reported a similar or decreased referral rate [16, 17] at FFDM. Our 3% referral rate at FFDM is still lower than the one observed in most other digital screening mammography programs, but it is in accordance with the recommended referral rate in the European guidelines for quality assurance in breast cancer screening and diagnosis [18] . We found a significantly higher overall cancer detection rate at FFDM, and most of these extra cases (1.4‰ out of 1.7‰ screens) either showed microcalcifications or microcalcifications associated with a density, which is in line with previous studies [3] [4] [5] [6] [7] 15] . In another study, a higher detection rate at FFDM was observed only for cancers depicted as clustered microcalcifications [4] . Another Dutch study also reported a better depiction of Invasive cancers with tumor-node-metastases stage IIA or higher, i.e. tumor size exceeding 20 mm (T2) and/or the presence of lymphatic metastasis in the sentinel node or axillary lymph nodes.
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microcalcifications at FFDM, leading to a higher SNCB rate [7] . Finally, several investigators found similar detection rates at FFDM and SFM [17, 19] . In our study, the detection rate at SFM was similar for initial and subsequent screens, whereas a higher detection rate for initial screens was observed in another Dutch study by Fracheboud et al. [20] . This contradictory finding may be due to differences in study populations. Many women would have been included several times by Fracheboud et al. during their much longer inclusion period, whereas women in our study were included only once in the group of analog screens. Also, a potentially higher detection rate at initial screens may have been compensated by an increased baseline cancer risk for women at subsequent screening, as the mean age will be higher for the latter group.
In contrast to most other studies [3-5, 14, 17] , we observed a significantly lower positive predictive value of referral at FFDM, compared with SFM. The Dutch nation-wide SFM program has always been characterized by a very low referral rate of <1.5% [5, 9] and the referral rate at digital screening of 3.0%, which was observed in our study, has inevitably resulted in a lower positive predictive value. Yet, our positive predictive value of 21.9% is still considerably higher than those reported in other FFDM studies [3, 5] and one should try to minimize false-positive referrals as these women may experience considerable and sustained psychological distress [21, 22] .
In both screening groups, 51% of the referred women underwent biopsy in addition to diagnostic breast imaging procedures. The positive predictive value of percutaneous biopsy decreased from 62.8% at SFM to 42.9% at FFDM and the latter percentage is comparable with those reported in other studies [3, 5] . The increased overall referral rate at FFDM was mainly due to improved detection of densities and clustered microcalcifications. The increased detection of lesions presenting as microcalcifications resulted in an almost fourfold increase in stereotactic core needle biopsies per 1000 screened women and, despite an improved cancer detection rate, in a marked decrease of the positive predictive value of stereotactic biopsies from 40.0% to 26.9%. The increased use of stereotactic core needle biopsy at digital screening will have a great impact on the daily practice of the regional breast clinics as it is much more time consuming than ultrasound-guided biopsy.
There are very few data available comparing tumor characteristics of cancers detected at SFM and FFDM. We identified a higher proportion of low-to intermediate-grade DCIS at FFDM. Sparsely available studies on DCIS have shown conflicting results. In accordance with our findings, a US study identified a higher proportion of low-to intermediate-grade DCIS at FFDM [4] . However, a Scandinavian study found a higher proportion of high-grade cases which approached statistical significance [23] . These discrepancies are interesting as they may reflect differences in screening education and differences in referral guidelines for microcalcification abnormalities detected at screening mammography.
The proportion of advanced cancers was significantly lower at FFDM, due to an increase in the detection of smaller, lymph-node-negative cancers. In line with an Irish study, we also found a significantly higher proportion of low-grade invasive tumors at FFDM, while more grade 2 and 3 tumors were identified at SFM [24] . Finally, rates of progesteronepositive, estrogen-positive and Her2/Neu-negative invasive cancers were increased at FFDM. The rates of triple-negative invasive cancers did not change. We did not find any previously published data on receptor characteristics of cancers detected at FFDM to compare our results with.
To our knowledge, our study is the first that addresses the influence of transition from SFM to FFDM on the surgical treatment of screen-detected cancer. There are conflicting reports as to whether the mastectomy rate is higher in screened than in non-screened women [25, 26] . Our data show that tumors detected by FFDM were more likely to be treated with breast-conserving surgery. The mastectomy rate was similar for both groups, and thus, transition to FFDM does not increase a woman's chance to undergo mastectomy.
A potentially harmful effect of screening is the phenomenon of the so-called over-diagnosis of breast cancers, i.e. diagnosis of breast cancers that, if left undiscovered, would never become clinically evident and, thus, would never become lethal. The detection rate of DCIS more than doubled at FFDM (from 0.7 to 1.6), with a significantly larger proportion of low-to intermediate-grade DCIS, whereas the enhanced detection rate of invasive cancers was less profound (from 4.2 to 5.1). Estimates of over-diagnosis vary greatly among studies, from 2% to 50%, and may be explained by the length of the follow-up to allow for lead time, or by the denominator that is used to define the population at risk [26] [27] [28] . De Gelder et al. [8] calculated that the proportion of over-diagnosed cancers at the Dutch nation-wide breast screening program will increase from 2.1% at SFM to 2.5% at FFDM, without a further significant reduction in breast cancer mortality. Our findings of a marked increase in small invasive cancers and low-to-intermediate DCIS at FFDM suggest that the proportion of over-diagnosed cancers is probably higher than the one mentioned by de Gelder et al. [8] .
Our study has certain limitations. Although all screening radiologists received training on digital screening mammography at the National Expert and Training Centre for Breast Cancer Screening before the implementation of FFDM and all radiologists had >5 years experience with working in a digital radiology environment, none of them had experience with the use of FFDM in screening at the start of the study. It is unlikely, however, that our results will have been influenced by a 'learning effect', as the referral rate, cancer detection date and positive predictive value of referral were similar for the first and second half of the inclusion period for digital screens. The FFDM group was restricted to women who were digitally screened for their first time and we cannot predict the long-term impact of successive digital screening rounds on the screening outcome. However, a recent Dutch study found that referral rates at successive digital screening decreased and stabilized at a higher level than in conventional screening, yet with significantly enhanced cancer detection [6] . We could not determine the screening sensitivity at FFDM as follow-up should be continued until the next biennial screen in order to detect all interval cancers.
Finally, we are not certain whether the routine comparison of digital screens with previous analog screens that had been digitized, rather than comparison with the original hard copy original articles Annals of Oncology analog screens, may have had some effect on the screening results.
In summary, we conclude that the transition from SFM to FFDM resulted in a significantly enhanced cancer detection rate for DCIS and invasive cancers, at the expense of an increased referral rate and decreased positive predictive value of referral and biopsy. Invasive cancers detected at FFDM were more frequently of low grade, showed less lymph node involvement and were more frequently progesterone-receptor positive. Women with breast cancer detected at FFDM were more likely to be treated by breast-conserving surgery, while the mastectomy rate was similar at SFM and FFDM.
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